Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02601248 | Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor | PHASE1 | COMPLETED | 24 | — | — | Oct 1, 2012 | May 1, 2016 | Feb 13, 2020 | 1 | China |
for each patient, adverse events are collected from the date of consent until 30 days after trial discontinuation
| Arm | Type | Description |
|---|---|---|
| Theliatinib | EXPERIMENTAL | Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage . |
| Name | Type | Description |
|---|---|---|
| Theliatinib | DRUG | Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily |
Inclusion Criteria: * Histopathology confirmed solid tumors * Failed to standard treatment or no standard treatments for uncontrolled, recurrent and/or metastatic advance tumor (whatever previous surgery conditions) * Age 18-75 * Performance status of 0, or 1, and no worse within 7days * Life expec...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |